EveT.RodlerMD

Oncology • Sacramento, CA

Co-Chief Hematology/Oncology, Veterans Administration, Martinez, CA

Join to view full profile

Dr. Rodler is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rodler's full profile

Already have an account?

Office
2279 45th St
Sacramento, CA 95817
Phone+1 916-734-5959

Fax+1 916-703-5265

Education & Training

University of California Davis HealthFellowship, Hematology and Medical Oncology, 2001 - 2004
Los Angeles County-Harbor-UCLA Medical CenterResidency, Internal Medicine, 1997 - 2000
George Washington University School of Medicine and Health SciencesClass of 1997

Certifications & Licensure

CA State Medical License 2013 - 2025
WA State Medical License 2007 - 2015
NJ State Medical License 2005 - 2009
IL State Medical License 2004 - 2005
American Board of Internal Medicine Medical Oncology

Clinical Trials

Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma Start of enrollment: 2010 Jul 01
Completed
Phase 3
Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma Start of enrollment: 2012 Apr 01
Completed
Not Applicable

Publications & Presentations

PubMed

Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131.
Karen L Smith, Fengmin Zhao, Ingrid A Mayer, Amye J Tevaarwerk, Sofia F Garcia
Cancer. 2024-05-15
26 citations
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo...
Eve Rodler, Priyanka Sharma, William E Barlow, Julie R Gralow, Shannon L Puhalla
The Lancet. Oncology. 2023-02-01
10 citations
A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastat...
Evan Rosenbaum, Rashmi Chugh, Christopher W Ryan, Mark Agulnik, Mohammed M Milhem
European Journal of Cancer. 2022-11-01